The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis

American Journal of Gastroenterology

Volumn 104, Issue 6, 2009, Pages 1468-1478

  Shen, Bo ^a   Pardi, Darrell S ^b   Bennett, Ana E ^a   Queener, Elaine ^a   Kammer, Patricia ^b   Hammel, Jefferey P ^a   LaPlaca, Caroline ^c   Harris, M Scott ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; AST 120; CIPROFLOXACIN; ITRACONAZOLE; METRONIDAZOLE; RIFAXIMIN; TINIDAZOLE;

ABSCESS; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANASTOMOSIS; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEITIS; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; TREATMENT RESPONSE; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; BIOPSY; CARBON; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSCOPY, GASTROINTESTINAL; FOLLOW-UP STUDIES; HUMANS; MALE; MICROSPHERES; MIDDLE AGED; OXIDES; PILOT PROJECTS; POUCHITIS; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67349235926     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.138     Document Type: Article

References (45)

1. Pardi DS, Sandborn WJ. Systematic review. The management of pouchitis. Aliment Pharmacol Ther 2006;23:1087-96.
2. Shen B, Fazio VW, Remzi FH et al. Clinical approach to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol 2005;100:2796-807.
3. Cheifetz A, Itzkowitz S. The diagnosis and treatment of pouchitis in inflammatory bowel disease. J Clin Gastroenterol 2004;38 (Suppl 1):S44-50.
4. Lovegrove RE, Tilney HS, Heriot AG et al. A comparison of adverse events and functional outcomes after restorative proctocolectomy for familial adenomatous polyposis and ulcerative colitis. Dis Colon Rectum 2006;49:1293-306.
5. Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg 2000;24:851-6.
6. Gionchetti P, Rizzello F, Venturi A et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 999;13:73-8.
7. Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 2003;124:1636-50.
8. Kmiot WA, Youngs D, Tudor R et al. Mucosal morphology, cell proliferation and faecal bacteriology in acute pouchitis. Br J Surg 1993;80:1445-9.
9. Shen B, Goldblum JR, Hull TL et al. Clostridium difficile- associated pouchitis. Dig Dis Sci 2006;51:2361-4.
10. Shen B, Jiang Z-D, Fazio VW et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008;6:782-8.
11. Ohge H, Furne JK, Springfeld J et al. Association between fecal hydrogen sulfide production and pouchitis. Dis Colon Rectum 2005;48:469-75.
12. Natori H, Utsunomiya J, Yamamura T et al. Fecal and stomal bile acid composition after ileostomy or ileoanal anastomosis in patients with chronic ulcerative colitis and adenomatosis. Gastroenterology 1992;102:1278-87.
13. Salemans JMJ, Nagengast FM. Clinical and physiological aspects of ileal pouch-anal anastomosis. Scand J Gastroenterol 1996;30 (Suppl 212):3-12.
14. Nasmyth DG, Johnston D Williams NS et al. Changes in the absorption of bile acids after total colectomy in patients with an ileostomy or pouch-anal anastomosis. Dis Colon Rectum 1989;32:230-4.
15. Lerch MM, Braun J, Harder M et al. Postoperative adaptation of the small intestine after total colectomy and J-pouch-anal anastomosis. Dis Colon Rectum 989;32:600-8.
16. De Silva HJ, Kettlewell M, Mortensen MJ et al. Mucosal characteristics of pelvic ileal pouches. Gut 1991;32:61-5.
17. Sauser P, Fitsher A, Riedel HD et al. Reduced transcription of ileal bile acid transporters during chronic ileal inflammation in man. Gastroenterology 2000;118:A4296.
18. Levitt MD, Kuan M. The physiology of ileo-anal pouch function. Am J Surg 998;176:384-9.
19. Breuer NF, Rampton DS, Tammar A et al. Efect of colonic perfusion with sulfated and non-sulfated bile acids on mucosal structure and function in the rat. Gastroenterology 1983;84:969-77.
20. Merrett MN, Crotty BJ, Mortensen N et al. Ileal pouch dialysate is cytotoxic to I-407 and HT-29 cells: bile may be the active factor. Gut 1991;32:A1205.
21. Meagher AP, Farouk R, Dozois RR et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998;85:800-3.
22. Lohmuller JL, Pemberton JH, Dozois RR et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990;21:622-7; discussion 627-629.
23. Hurst RD, Molinari M, Chung TP et al. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996;131:497-500;discussion 501-502.
24. Sambuelli A, Boerr L, Negreira S et al. Budesonide enema in pouchitis-a double-blind, double-dummy controlled trial. Aliment Pharmacol Ther 2002;16:27-34.
25. Miner P Jr, Wedel M, Bane B et al. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesió n molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004;19:281-6.
26. Gionchetti P, Rizzello F, Morselli C et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007;50:2075-82.
27. Owada A, Nakao M, Koike J et al. Efects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int 1997;63 (Suppl): S88 -90.
28. Fukuda Y, Takazoe M, ugita A et al. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2008;103:1721-929.
29. Niwa T, Nomura T Sugiyama S et al. The protein metabolite hypothesis, a model for the progression of renal failure. An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997;52 (Suppl):S23-8.
30. Niwa T, Tsukushi S, Ise M et al. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrolyte Metab 1997;23:179-84.
31. Sandborn WJ, Tremaine WJ, Batts KP et al. Pouchitis afer ileal pouchanal anastomosis: a pouchitis disease activity index. Mayo Clin Proc 1994;69:409-15.
32. Madden MV, McIntyre AS, Nicholls RJ. Double-blinded crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994;39:1193-6.
33. Shen B, Achkar JP, Lashner BA et al. A randomized trial of ciprofloxacin and metronidazole in treating acute pouchitis. Inflamm Bowel Dis 2001;7:301-5.
34. Isaacs KL, Sandler RS, Abreu M et al. Crohn's and Colitis Foundation of America Clinical Alliance. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007;13:1250-5.
35. Mimura T, Rizzello R, Helwig U et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909-17.
36. Shen B, Fazio VW, Remzi FH et al. Combined ciprofoxacin and tinidazole in the treatment of chronic refractory pouchitis. Dis Colon Rectum 2007;50:498-508.
37. Gionchetti P, Rizzello F, Poggioli G et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007;25:1231-6.
38. Calabrese C, Gionchetti P, Rizzello F et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther 2008;27:759-64.
39. Shen B, Brzezinski A, Fazio VW et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005;22:721-8.
40. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
41. Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-14.
42. Welters CFM, Heineman E, Thunnissen BJM et al. Efect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum 2002;45:621-7.
43. Parsi MA, Shen B, Achkar JP et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004;126:1280-6.
44. Shen B, Achkar J-P, Lashner BA et al. Endoscopic and histologic evaluations together with symptom assessment are required to diagnose pouchitis. Gastroenterology 2001;121:26-7.
45. Shen B, Lashner BA, Achkar J-P et al. Modifed pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum 2003;46:748-53.